US biotech firm Novavax has said that its Covid-19 vaccine was 89.3% effective in preventing the killer virus in a trial conducted in the United Kingdom
The world's largest vaccine manufacturer, the Serum Institute of India (SII), has sought the Drugs Controller General of India's (DCGI) permission to conduct a small domestic trial of the Novavax coronavirus vaccine that was found to be 89.3% effective in a UK trial, its Chief Executive Officer Adar Poonawalla told news agency Reuters on Friday
Earlier today, Novavax said that its Covid-19 vaccine was 89.3% effective in preventing the killer virus in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in Britain, as per a preliminary analysis.
Novavax is reportedly stockpiling Covid-19 vaccines at six operating manufacturing sites and said it expects a total of eight plants in seven countries to produce at the rate of 2 billion doses per year, including from the SII, a major player in the fight against coronavirus.
A mid-stage trial of its coronavirus vaccine in South Africa, where a troubling new variant of the deadly virus is common, showed 60% effectiveness among people who did not have HIV.
Last year in September, Novavax had announced its deal with the world's largest vaccine manufacturing firm SII in order to produce 2 billion doses of coronavirus vaccines.
As per reports, Novavax has said that it started making new versions of its Covid-19 vaccine to protect against emerging virus variants in early January and expects to select ideal candidates for a booster in the coming days.
The company also said that it plans to initiate clinical testing of these new vaccines in the second quarter of this year.
Novavax has also received around $388 million in backing from the Coalition for Epidemic Preparedness Innovation (CEPI), a Norway-based group backed by 14 governments, the Bill and Melinda Gates Foundation, and Britain’s Wellcome Trust.
Source - liveMint
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.